FIELD: medicine. SUBSTANCE: this method prescribes intranasally administering thymogen 48 to 72 h after start of cure in dose of 100 mcg during seven days. EFFECT: disclosed method allows relieving disease, preventing allergic complications and undertaking cure both in hospital and ambulatory conditions. 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT PREVENTING DEGRANULATION OF MAST CELLS | 1992 |
|
RU2030914C1 |
| METHOD FOR TREATING PATIENTS SUFFERING FROM ATOPIC DERMATITIS | 1992 |
|
RU2068696C1 |
| METHOD FOR TREATMENT OF SINUSITIS IN CHILDREN | 0 |
|
SU1642398A1 |
| METHOD FOR TREATING ACUTE AND CHRONIC NONSPECIFIC PULMONARY DISEASES | 1993 |
|
RU2088281C1 |
| METHOD FOR TREATING STAPHYLOCOCCUS INFECTION | 0 |
|
SU1748827A1 |
| METHOD OF PREVENTING KERATOTRANSPLANT REJECTION CRISIS | 0 |
|
SU1814073A1 |
| THERAPEUTIC AGENT FOR ENHANCING TISSUE OXYGENATION IN DIABETIC FOOT, AND A METHOD FOR USE THEREOF | 2017 |
|
RU2717674C1 |
| METHOD FOR TREATING ACUTE CEREBRAL STROKE CASES | 2005 |
|
RU2268064C1 |
| PEPTIDE POSSESSING IMMUNOGEROPROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR ITS USING | 2006 |
|
RU2301074C1 |
| METHOD OF DETERMINING INDIVIDUAL SENSITIVITY OF BRONCHIAL ASTHMA PATIENTS TO TYMUS PREPARATION | 0 |
|
SU1193585A1 |
